Nurix Therapeutics, Inc.
US ˙ NasdaqGM ˙ US67080M1036

SecurityNRIX / Nurix Therapeutics, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership921,322 shares
Ownership 1.90%
State Street Corp ownership in NRIX / Nurix Therapeutics, Inc.

2024-01-23 - State Street Corp has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 921,322 shares of Nurix Therapeutics, Inc. (US:NRIX). This represents 1.9 percent ownership of the company. In their previous filing dated 2023-02-10 , State Street Corp had reported owning 2,507,987 shares, indicating a decrease of -63.26 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2024-01-23 2024-01-23 13G/A 2,507,987 921,322 -63.26 1.90 -64.29
2023-02-10 2023-02-10 13G 2,507,987 5.32

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NURIX THERAPEUTICS COM 67080M103 5,141,195 1,581,694 44.44 79,689 18.02 0.0028
2026-02-13 2025-12-31 13F NURIX THERAPEUTICS COM 67080M103 3,559,501 697,114 24.35 67,524 155.30 0.0023
2025-11-14 2025-09-30 13F NURIX THERAPEUTICS COM 67080M103 2,862,387 330,233 13.04 26,448 -8.30 0.0009
2025-08-14 2025-06-30 13F NURIX THERAPEUTICS COM 67080M103 2,532,154 -329,066 -11.50 28,841 -15.15 0.0011
2025-05-15 2025-03-31 13F NURIX THERAPEUTICS COM 67080M103 2,861,220 57,960 2.07 33,991 -35.64 0.0014
2025-02-14 2024-12-31 13F NURIX THERAPEUTICS COM 67080M103 2,803,260 431,989 18.22 52,813 -0.88 0.0021
2024-11-14 2024-09-30 13F NURIX THERAPEUTICS COM 67080M103 2,371,271 -337,262 -12.45 53,282 -5.74 0.0022
2024-08-14 2024-06-30 13F NURIX THERAPEUTICS COM 67080M103 2,708,533 -20,803 -0.76 56,527 40.89 0.0025
2024-05-15 2024-03-31 13F NURIX THERAPEUTICS COM 67080M103 2,729,336 1,808,014 196.24 40,121 321.97 0.0018
2024-02-14 2023-12-31 13F NURIX THERAPEUTICS COM 67080M103 921,322 -852,746 -48.07 9,508 -31.81 0.0005
2023-11-14 2023-09-30 13F NURIX THERAPEUTICS COM 67080M103 1,774,068 -151,658 -7.88 13,944 -27.52 0.0008
2023-08-14 2023-06-30 13F NURIX THERAPEUTICS COM 67080M103 1,925,726 -309,552 -13.85 19,238 -3.08 0.0010
2023-05-15 2023-03-31 13F NURIX THERAPEUTICS COM 67080M103 2,235,278 -272,709 -10.87 19,849 -27.92 0.0011
2023-05-15 2022-12-31 13F/A-99 NURIX THERAPEUTICS COM 67080M103 2,507,987 195,763 8.47 27,538 -8.60 0.0016
2023-05-15 2022-12-31 13F NURIX THERAPEUTICS COM 67080M103 2,507,987 195,763 27,538 0.0016
2022-11-15 2022-09-30 13F NURIX THERAPEUTICS COM 67080M103 2,312,224 195,453 9.23 30,128 12.34 0.0019
2022-08-15 2022-06-30 13F NURIX THERAPEUTICS COM 67080M103 2,116,771 -185,773 -8.07 26,819 -16.86 0.0016
2022-05-16 2022-03-31 13F NURIX THERAPEUTICS COM 67080M103 2,302,544 744,832 47.82 32,259 -28.47 0.0016
2022-02-14 2021-12-31 13F NURIX THERAPEUTICS COM 67080M103 1,557,712 -75,419 -4.62 45,096 -7.83 0.0021
2021-11-15 2021-09-30 13F NURIX THERAPEUTICS COM 67080M103 1,633,131 -226,337 -12.17 48,929 -0.82 0.0026
2021-08-16 2021-06-30 13F NURIX THERAPEUTICS COM 67080M103 1,859,468 481,606 34.95 49,332 15.16 0.0026
2021-07-09 2021-03-31 13F/A-1 NURIX THERAPEUTICS COM 67080M103 1,377,862 926,630 205.36 42,838 188.72 0.0025
2021-05-17 2021-03-31 13F NURIX THERAPEUTICS COM 67080M103 1,377,862 926,630 42,838 0.0025
2021-02-16 2020-12-31 13F NURIX THERAPEUTICS COM 67080M103 451,232 319,559 242.69 14,837 222.75 0.0009
2020-11-10 2020-09-30 13F NURIX THERAPEUTICS COM 67080M103 131,673 131,673 4,597 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.